Return to content in this issue


Exacerbation Rate Reduction With Mepolizumab Stratified by Maintenance Oral Corticosteroids Use and Eosinophil Levels: A Post Hoc Analysis of the DREAM and MENSA Studies

Bobolea I1, Bañas D2, Melero C3, de Andrés AI2, Joksaite S2, Sánchez-Herrero G2

1Allergy Section, Severe Asthma Unit. Department of Pulmonology and Allergy, Hospital Clinic Barcelona–Institute for Health Research (IdiBAPS), Barcelona, Spain
2GSK, Madrid, Spain
3Hospital 12 de Octubre Institute for Health Research (i+12), Madrid, Spain

J Investig Allergol Clin Immunol 2022; Vol 32(2) : 148-150
doi: 10.18176/jiaci.0714

Key words: Asthma, Eosinophils, Exacerbations, Mepolizumab, Oral corticosteroids (OCS)